Although this thrombocytopenia could be diminished by treating patients with 150 mg navitoclax/day for one week followed by therapeutic does of 325 mg daily10, maximal BCL2 inhibition was never achieved in lymphoid malignancies because of toxicities of BCLXL inhibition in other normal tissues. Here, BCL2L1 is linked to Thrombocytopenia.